James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

Nigel Langley of gChem stresses excipient innovation, safer solvents, and supply chain resilience for pharma’s future in part ...

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...

On September 9, 2025, President Trump issued a Presidential Memorandum directing the Secretary of Health and Human Services ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

Q3 2025 Earnings Call Transcript October 29, 2025 Bausch Health Companies Inc. misses on earnings expectations. Reported EPS is $0.4798 EPS, expectations were $1.07. Operator: Greetings, and welcome ...

Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsJon Cohen - CEO & DirectorIan Harris - Chief ...

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary outcome measures, and ...

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstr ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical ...